Scholarlink

Introduction <p>In the face of increasing antimicrobial resistance, ESKAPE pathogens—<Emphasis Type="BoldItalic">Enterococcus faecium</Emphasis><b>, </b><Emphasis Type="BoldItalic">Staphylococcus aureus</Emphasis><b>, </b><Emphasis Type="BoldItalic">Klebsiella pneumoniae</Emphasis><b>, </b><Emphasis Type="BoldItalic">Acinetobacter baumannii</Emphasis><b>, </b><Emphasis Type="BoldItalic">Pseudomonas aeruginosa, and Enterobacter species</Emphasis>—pose a significant threat to public health, particularly in nosocomial settings.</p> Areas covered <p>This review explores the potential of targeting protein adenylyltransferase (PrAT) as a therapeutic strategy against these multidrug-resistant bacteria. We discuss the mechanisms of PrAT activity, its involvement in reduction–oxidation (redox) homeostasis, and the rationale for its potential as a drug target against ESKAPE pathogens.</p> Expert opinion <p>PrAT plays an essential role in sustaining the bacterium’s redox homeostasis, a vital aspect of bacterial survival, by interacting with glutaredoxin (Grx). Future research should focus on elucidating the specific role of PrAT in ESKAPE pathogens, with an emphasis on studying the enzyme’s function and designing targeted inhibitors. This review underscores the importance of continued investigation into PrAT in ESKAPE pathogens as a critical step in addressing the challenges of antimicrobial resistance in clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring protein adenylyltransferase as a therapeutic target for combating ESKAPE pathogens in hospital-acquired infections

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月7日

查看全文
  • Reabetswe Maake,
  • Sarah Otun,
  • Ikechukwu Achilonu

摘要

Introduction

In the face of increasing antimicrobial resistance, ESKAPE pathogens—Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species—pose a significant threat to public health, particularly in nosocomial settings.

Areas covered

This review explores the potential of targeting protein adenylyltransferase (PrAT) as a therapeutic strategy against these multidrug-resistant bacteria. We discuss the mechanisms of PrAT activity, its involvement in reduction–oxidation (redox) homeostasis, and the rationale for its potential as a drug target against ESKAPE pathogens.

Expert opinion

PrAT plays an essential role in sustaining the bacterium’s redox homeostasis, a vital aspect of bacterial survival, by interacting with glutaredoxin (Grx). Future research should focus on elucidating the specific role of PrAT in ESKAPE pathogens, with an emphasis on studying the enzyme’s function and designing targeted inhibitors. This review underscores the importance of continued investigation into PrAT in ESKAPE pathogens as a critical step in addressing the challenges of antimicrobial resistance in clinical practice.